Nautilus Biotechnology Gears Up for Investor Engagement
SEATTLE — Nautilus Biotechnology, Inc. (NASDAQ: NAUT), an innovator in single-molecule protein analysis, has announced its upcoming participation in several key investor conferences this September. This involvement represents an exciting opportunity for Nautilus to engage with the investment community and showcase its unique technological advancements.
Upcoming Conferences and Presentations
The first event on the calendar is the prestigious Morgan Stanley 23rd Annual Global Healthcare Conference, taking place in New York City. During this significant event, Nautilus's management is scheduled to participate in a fireside chat on September 8 at 10:50 a.m. Pacific Time / 1:50 p.m. Eastern Time. This chat will provide insights into the company's vision and innovation in the field of biotechnology.
Q3 Investor Summit Group Virtual Conference
In addition to the Morgan Stanley event, Nautilus will also present at the Q3 Investor Summit Group Virtual Conference. This presentation is set for September 16 at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time, offering investors a deep dive into the company's technology and progress. Furthermore, management will engage in one-on-one meetings on the following day, September 17, providing further opportunities for individual interactions with investors.
Access to Conference Presentations
For those interested in following Nautilus's presentations, both live and archived webcasts will be available on the "Investors" section of the company's website. This accessibility allows a broader audience to engage with Nautilus's pioneering work and growth trajectory.
Introducing Nautilus Biotechnology
Nautilus Biotechnology is not just a company; it's a mission to transform the landscape of proteomics. Headquartered in Seattle, Washington, and with research operations in San Carlos, California, the company is developing a platform that aims to quantify and unlock the complexity inherent in the proteome. By democratizing access to proteomic data, Nautilus is setting the stage for substantial advancements in human health and medicine.
Company Contact Information
For media inquiries, please reach out to press@nautilus.bio. Investors can contact the company at investorrelations@nautilus.bio. This dual-channel approach ensures that both the media and investors have clear communication paths to engage with Nautilus.
Frequently Asked Questions
What is Nautilus Biotechnology known for?
Nautilus Biotechnology is recognized for its innovations in single-molecule protein analysis and its pioneering platform technology in the field of proteomics.
When will Nautilus participate in the Morgan Stanley conference?
Nautilus is scheduled to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8.
How can investors watch the company's presentations?
Investors can access live and archived webcasts of Nautilus's presentations through the “Investors” section of the company's website.
Where is Nautilus Biotechnology headquartered?
Nautilus Biotechnology is headquartered in Seattle, Washington, with research facilities in San Carlos, California.
Who can I contact for media inquiries about Nautilus?
Media inquiries can be directed to press@nautilus.bio for further information.
